0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Complement C1s

Complement C1s

Brief Information

Name:Complement C1s
Target Synonym:EC:3.4.21.42,EC 3.4.21,C1 esterase,Complement component 1 subcomponent s,C1S,Complement C1s,Complement Component 1, S Subcomponent,Basic Proline-Rich Peptide IB-1,Complement C1s Subcomponent,EC 3.4.21.42,EDSPD2
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
COS-H52H3 Human Human Complement C1s Protein, His Tag
COS-H52H3-structure
COS-H52H3-sds
ACRO Quality

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Conestat alfa rhC1-INH Approved Pharming Group Nv Rhucin, Esterasine, Ruconest EU Angioedemas, Hereditary Pharming Group Nv 2010-10-28 Rejection of renal transplantation; Myocardial Infarction; Renal Insufficiency; Rejection of organ transplantation; Genetic Diseases, Inborn; Coronavirus Infections; Non-ST Elevated Myocardial Infarction; Angioedema; Angioedemas, Hereditary Details
Sutimlimab BIVV-009; TNT-009 Approved True North Therapeutics ENJAYMO United States Anemia, Hemolytic, Autoimmune Bioverativ Therapeutics Inc 2022-02-04 Hemolysis; Purpura, Thrombocytopenic, Idiopathic; Anemia, Hemolytic, Autoimmune; Pemphigoid, Bullous; Kidney Failure, Chronic Details
Complement C1 inhibitor protein (Shire ViroPharma) C1 INH-nf; C1-INH; SHP-616 Approved Sanquin Plasma Products Bv Cinryze, Cetor United States Angioedemas, Hereditary null 2008-10-10 Brain Injuries, Traumatic; Rejection of organ transplantation; Angioedemas, Hereditary Details
C1 esterase inhibitor (Human, CSL Behring) BI-3.012; CSL-830; CSL-842; CE-1145 Approved Csl Behring Llc Berinert, Haegarda, Berinert 2000 Japan Angioedemas, Hereditary Csl Behring Llc 1990-06-29 Hereditary Angioedema Types I and II; Angioedemas, Hereditary Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Riliprubart SAR-445088; TNT-020; BIVV-020 Phase 3 Clinical True North Therapeutics Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Polyneuropathies; Rejection of organ transplantation; Anemia, Hemolytic Details
C1 esterase inhibitor (Boya Bio-Pharmaceutical) Phase 3 Clinical Boya Bio-Pharmaceutical Group Co Ltd Angioedemas, Hereditary Details
Complement-C1 inhibitor protein (Octapharma) Phase 2 Clinical Octapharma Angioedemas, Hereditary Details
DNTH-103 DNTH-103; DNTH103 Phase 2 Clinical Dianthus Therapeutics Inc Myasthenia Gravis; Autoimmune Diseases Details
C1 esterase inhibitor (Chengdu Institute of Biological Products) Phase 1 Clinical Chengdu Institute Of Biological Products Co Ltd Angioedemas, Hereditary Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken